Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases Post author:andrewkaretas Post published:November 18, 2024 Post category:Dual/Scientific Publications Continue ReadingPreclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
ALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study Post author:andrewkaretas Post published:November 7, 2024 Post category:CD70/Scientific Publications Continue ReadingALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study
November 7, 2024 5:00 PM EST : Allogene Therapeutics Third Quarter 2024 Conference Call Post author:andrewkaretas Post published:November 7, 2024 Post category:Events Continue ReadingNovember 7, 2024 5:00 PM EST : Allogene Therapeutics Third Quarter 2024 Conference Call
New Frontiers for CAR-T Post author:andrewkaretas Post published:November 1, 2024 Post category:Perspectives Continue ReadingNew Frontiers for CAR-T
October 1, 2024 1:00 PM EDT : Goldman Sachs Cell Therapy Day Conference Post author:andrewkaretas Post published:September 27, 2024 Post category:Events Continue ReadingOctober 1, 2024 1:00 PM EDT : Goldman Sachs Cell Therapy Day Conference
September 11, 2024 10:15 AM EDT : Baird 2024 Global Healthcare Conference Post author:andrewkaretas Post published:August 13, 2024 Post category:Events Continue ReadingSeptember 11, 2024 10:15 AM EDT : Baird 2024 Global Healthcare Conference
August 13, 2024 10:00 AM EDT : Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase Post author:andrewkaretas Post published:August 7, 2024 Post category:Events Continue ReadingAugust 13, 2024 10:00 AM EDT : Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
August 7, 2024 5:00 PM EDT : Allogene Therapeutics Second Quarter 2024 Conference Call Post author:andrewkaretas Post published:July 31, 2024 Post category:Events Continue ReadingAugust 7, 2024 5:00 PM EDT : Allogene Therapeutics Second Quarter 2024 Conference Call
ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy Post author:andrewkaretas Post published:July 15, 2024 Post category:Uncategorized Continue ReadingALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy
FT US Pharma and Biotech Summit Post author:andrewkaretas Post published:June 12, 2024 Post category:Perspectives/Uncategorized Continue ReadingFT US Pharma and Biotech Summit
